Entecavir therapy in Turkish adult patients with chronic hepatitis B: One-year results from Izmir Province, Turkey

Hepatitis Monthly

Volumn 10, Issue 3, 2010, Pages 183-187

  Kose, Sukran ^a   Ulusoy, Melda Turken ^a   Akkoclu, Gulgun ^a   Gozaydin, Ayhan ^a  

^a Tepecik Research and Training Hospital   (Turkey)

Author keywords

Entecavir; Hepatitis B; Treatment

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE;

ADULT; ARTICLE; CHRONIC DISEASE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; SEROCONVERSION; TREATMENT DURATION; TURKEY (REPUBLIC); VIRUS REPLICATION;

EID: 77954869533     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Maddrey WC. Hepatitis B: an important public health issue. J Med Virol. 2000;61(3):362-6.
2. Keskinler DU. [Serologic Evaluation for HBV and HCV of Blood Donors Applying to Red-Crescent Blood Bank in Erzurum]. J Inonu Univ Med Faculty 2003;10(4):195-8.
3. Kao JH, Chen DS. The natural history of hepatitis B virus infection. In: Lai CL, Locarnini S, editors. Hepatitis B Virus. 1st ed. London: International Medical Press; 2002. p. 161-72.
4. Kangin M, Turhanoglu M, Gulsun S, Cakabay B. Seroprevalence of Hepatitis B and C among Children in Endemic Areas of Turkey. Hepat Mon. 2010;10(1):36-41.
5. Uyar Y, Cabar C, Balci A. Seroprevalence of Hepatitis B Virus among Pregnant Women in Northern Turkey. Hepat Mon. 2009;9(2):146-9.
6. Gurol E, Saban C, Oral O, Cigdem A, Armagan A. Trends in hepatitis B and hepatitis C virus among blood donors over 16 years in Turkey. Eur J Epidemiol. 2006;21(4):299-305.
7. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125(6):1714-22.
8. Rivkin A. A review of entecavir in the treatment of chronic hepatitis B infection. Curr Med Res Opin. 2005;21(11):1845- 56.
9. Tenney DJ, Pokornowski KA, Rose RE, et al. Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naive patients. J Hepatol. 2009;50(Suppl 1):S10.
10. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Longterm therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131(6):1743-51.
11. Idilman R, Kaymakoglu S, Oguz Onder F, et al. A short course of add-on adefovir dipivoxil treatment in lamivudineresistant chronic hepatitis B patients. J Viral Hepat. 2009;16(4):279-85.
12. Yenice N, Mehtap O, Ari{dotless}can N, Gökden Y. [The Lamuvidine monotherapy, interpheron alpha monotherapy and combination therapy in chronic hepatitis B infection]. Akademik Gastroenteroloji Dergisi. 2006;5(1):31-5.
13. Akhan S, Gürel E, Sayan M. [Evaluation of Treatment Results of Patients with Chronic Hepatitis B Followed for Five Years]. Klimik J. 2009;22(3):82-7.
14. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45(2):507-39.
15. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354(10):1001-10.
16. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354(10):1011-20.
17. Nagasaki F, Niitsuma H, Ueno Y, et al. The high incidence of the emergence of entecavir-resistant mutants among patients infected with lamivudine-resistant hepatitis B virus. Tohoku J Exp Med. 2007;213(2):181-6.
18. Tillmann HL. Antiviral therapy and resistance with hepatitis B virus infection. World J Gastroenterol. 2007;13(1):125-40.
19. Sayan M, Hulagu S, Karatayli SC. Multidrug-Resistant Hepatitis B Virus Strain in a Chronic Turkish Patient. Hepat Mon. 2010;10(2):141-6.
20. Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigenpositive chronic hepatitis B. Hepatology. 2010;51(2):422-30.